Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01491113 |
|
Recruitment Status :
Completed
First Posted : December 13, 2011
Results First Posted : January 10, 2014
Last Update Posted : February 10, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Healthy Subjects Renal Impairments | Drug: Levetiracetam 250 mg Drug: Levetiracetam 500 mg | Phase 4 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 30 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Basic Science |
| Official Title: | Single-Dose Pharmacokinetics of Orally Administered Levetiracetam (LEV) in Japanese Subjects With Normal Renal Function and Various Degrees of Renal Impairment Using a Dosing Regimen Adjusted to Renal Function (250 mg or 500 mg) |
| Study Start Date : | November 2011 |
| Actual Primary Completion Date : | November 2012 |
| Actual Study Completion Date : | November 2012 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Group A: Normal renal function
Subjects who have normal renal function (CLcr >80 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be taken through to Day 4 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.
|
Drug: Levetiracetam 500 mg
Tablet containing Levetiracetam 500 mg
Other Name: E-Keppra |
|
Experimental: Group B: Mild renal impairment
Patients who have mild renal impairment (50<CLcr <80 mL/min/1.73 m^2). Subjects will be orally administered (Levetiracetam) LEV 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 5 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.
|
Drug: Levetiracetam 500 mg
Tablet containing Levetiracetam 500 mg
Other Name: E-Keppra |
|
Experimental: Group C: Moderate renal impairment
Patients who have moderate renal impairment (30<CLcr < 50 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 6 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.
|
Drug: Levetiracetam 250 mg
Tablet containing Levetiracetam 250 mg
Other Name: E-Keppra |
|
Experimental: Group D: Severe renal impairment
Patients who have severe renal impairment (CLcr <30 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 7 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.
|
Drug: Levetiracetam 250 mg
Tablet containing Levetiracetam 250 mg
Other Name: E-Keppra |
|
Experimental: Group E: End-stage renal disease
Group E will receive Levetiracetam (LEV) 500 mg on Day 1, 44 hours (h) before the first hemodialysis. As a supplementary dose LEV 250 mg will be administered 1 h after the end of the first hemodialysis on Day 3. The 4-h Hemodialysis are scheduled as follows:
Safety assessments and blood samplings will be conducted until Day 7. Safety follow-up assessments will be performed on Day 10. Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 30, 44*, 44.25*, 44.5*, 45*, 46*, 47*, 48*, 49, 49.5, 50, 51, 53, 55, 57, 61, 73, 92, 96, 120, 140 hours post first dosing. 49 h-sample should be taken before the additional dose. The 44 h, 92 h, and 140 h sample should be taken before the start of the hemodialysis. *Inflow blood, outflow blood, and dialysate fluid will be collected. |
Drug: Levetiracetam 250 mg
Tablet containing Levetiracetam 250 mg
Other Name: E-Keppra Drug: Levetiracetam 500 mg Tablet containing Levetiracetam 500 mg
Other Name: E-Keppra |
- Maximum Observed Plasma Concentration (Cmax) of Ucb L059 (LEV) for Groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ]
Cmax refers to the maximum observed concentration of L059 (Levetiracetam).
Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
- Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L059 (LEV) From Baseline to the Last Quantifiable Concentration for Groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ]
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure.
Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
- Maximum Observed Plasma Concentration (Cmax) of Ucb L057 for Groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ]
Cmax refers to the maximum observed concentration of ucb L057.
Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
- Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L057 From Baseline to the Last Quantifiable Concentration for Groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ]
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure.
Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
- Maximum Observed Plasma Concentration (Cmax) of Ucb L059 (LEV) for Group E During First Period [ Time Frame: From Baseline to 44 hours post first dose ]Cmax refers to the maximum observed concentration of ucb L059 (Levetiracetam).
- Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L059 (LEV) From Baseline to 44 Hours for Group E [ Time Frame: From Baseline to 44 hours post first dose ]AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure.
- Maximum Observed Plasma Concentration (Cmax) of Ucb L057 for Group E During First Period [ Time Frame: From Baseline to 44 hours post first dose ]Cmax refers to the maximum observed concentration of ucb L057.
- Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L057 From Baseline to 44 Hours for Group E [ Time Frame: From Baseline to 44 hours post first dose ]AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure.
- Total Amount Excreted in Urine (Ae) of Ucb L059 (LEV) for Groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ]
Ae refers to the total amount of ucb L059 (Levetiracetam) excreted in urine.
Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
- Fraction of Dose Excreted in Urine (fe) of Ucb L059 (LEV) for Groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ]
fe refers to the fraction of dose excreted in urine of L059 (Levetiracetam).
Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
- Renal Clearance (CLR) of Ucb L059 (LEV) for Groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ]
Renal clearance describes the removal of drug from a volume of plasma in a given unit of time by the kidneys.
Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
- Apparent Total Body Clearance (CL/F) of Ucb L059 (LEV) for Groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ]
Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It indicates the volume of plasma (or blood) from which the drug is completely removed, or cleared, in a given time period.
Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
- Nonrenal Clearance (CLNR) of Ucb L059 (LEV) for Groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ]
The Non-Renal Clearance (CLNR) describes the removal of drug by organs other than the kidneys.
Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
- Total Amount Excreted in Urine (Ae) of Ucb L057 for Groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ]
Ae refers to the total amount of ucb L057 excreted in urine.
Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
- Renal Clearance (CLR) of Ucb L057 for Groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ]
Renal clearance describes the removal of drug from a volume of plasma in a given unit of time by the kidneys.
Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
- Apparent Total Body Clearance (CL/F) of Ucb L059 (LEV) for Group E During First Period [ Time Frame: From Baseline to 44 hours post first dose ]
Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It indicates the volume of plasma (or blood) from which the drug is completely removed, or cleared, in a given time period.
Geometric mean and Coefficient of Variation (CV) was not calculated since the extrapolated part of the AUC was greater than 20 %.
- Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L059 (LEV) for Groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ]
tmax refers to the time to reach maximum plasma concentration of ucb L059 (Levetiracetam).
Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
- Area Under the Concentration-time Curve (AUC) of Ucb L059 (LEV) From Baseline to Infinite for Groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ]
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure.
Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
- Terminal Half-life (t1/2) of Ucb L059 (LEV) for Groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ]
Terminal half-life refers to the time it takes for the concentrations to decrease by half.
Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
- Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L057 for Groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ]
tmax refers to the time to reach maximum plasma concentration (tmax).
Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
- Area Under the Concentration-time Curve (AUC) of Ucb L057 From Baseline to Infinite for Groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ]
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure.
Geometric mean and CV was not calculated since the extrapolated part of the AUC was greater than 20 %.
Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
- Terminal Half-life (t1/2) of Ucb L057 for Groups A to D [ Time Frame: From Baseline up to 144 hours post first dose ]
Terminal half-life refers to the time it takes for the concentrations to decrease by half.
Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
- Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L059 (Levetiracetam) for Group E During First Period [ Time Frame: From Baseline to 44 hours post first dose ]tmax refers to the time to reach the maximum plasma concentration of ucb L059 (Levetiracetam).
- Area Under the Concentration-time Curve (AUC) of Ucb L059 (LEV) From Baseline to Infinite for Group E [ Time Frame: From Baseline to 140 hours post first dose ]
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure.
Geometric mean and CV was not calculated since the extrapolated part of the AUC was greater than 20 %.
- Terminal Half-life (t1/2) of Ucb L059 (LEV) for Group E During First Period [ Time Frame: From Baseline to 44 hours post first dose ]
Terminal half-life refers to the time it takes for the concentrations to decrease by half.
Geometric mean and CV was not calculated since the extrapolated part of the AUC was greater than 20 %.
- Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L057 for Group E During First Period [ Time Frame: From Baseline to 44 hours post first dose ]tmax refers to the time to reach maximum plasma concentration (tmax).
- Hemodialysis Clearance (CLD) of Ucb L059 (LEV) During First Dialysis for Group E [ Time Frame: From 44 hours to 48 hours post first dose ]Calculated by the Arterio - Venous difference method and cumulative dialysate method.
- Ultrafiltration Clearance (CLUF) of Ucb L059 (LEV) During First Dialysis for Group E [ Time Frame: From 44 hours to 48 hours post first dose ]Calculated by the Arterio - Venous difference method and cumulative dialysate method.
- Hemodialysis Clearance (CLHD) of Ucb L059 (LEV) During First Dialysis for Group E [ Time Frame: From 44 hours to 48 hours post first dose ]Calculated according: CLHD=CLD+CLUF.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 20 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy subjects with normal renal function
- Subject is Japanese
- Subjects with creatinine clearance within 1 of 3 Groups (CLcr[mL/min/1.73 cm^2]: Group B: 50 - <80, Group C: 30 - <50, Group D: <30), or for Group E, subjects with end-stage renal failure undergoing hemodialysis
Exclusion Criteria:
- Subjects has taken any drug treatment, disease or injury to influence Levetiracetam PK except for renal impairments
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01491113
| Japan | |
| 1 | |
| Fukuoka, Japan | |
| 2 | |
| Ibaraki, Japan | |
| Study Director: | UCB Clinical Trial Call Center | +1 877 822 9493 (UCB) |
| Responsible Party: | UCB Pharma |
| ClinicalTrials.gov Identifier: | NCT01491113 |
| Other Study ID Numbers: |
N01373 |
| First Posted: | December 13, 2011 Key Record Dates |
| Results First Posted: | January 10, 2014 |
| Last Update Posted: | February 10, 2014 |
| Last Verified: | January 2014 |
|
Levetiracetam Oral administration Japanese |
Non-epileptic Healthy Renal impaired subjects |
|
Renal Insufficiency Kidney Diseases Urologic Diseases |
Levetiracetam Anticonvulsants Nootropic Agents |